Bryan Johnson, the tech tycoon-turned-biohacker, has become the poster child of the modern immortality movement. With a staggering $2 million annual budget dedicated to turning back his biological clock, Johnson’s name has become synonymous with high-tech health hacks. Whether it’s transfusing his son’s youthful blood or undergoing a full plasma exchange, Johnson has spared no expense — or headline — in his journey to “live forever.”

But in his latest confession, the 46-year-old entrepreneur may have uncovered a chilling irony: in his zeal to slow aging, he may have accelerated it.

Inspired by a 2009 study showing rapamycin extended the lifespan of mice by up to 14%, and a 2023 human trial in which 65% of participants felt healthier while on the drug, Johnson began meticulously adjusting his dosage to balance potential benefits and risks. But instead of rejuvenation, the tech mogul started noticing troubling side effects.

Mouth ulcers. Slow-healing wounds. Cholesterol imbalances. Spikes in blood sugar. But what truly alarmed Johnson was an uptick in his resting heart rate — a metric he considers the holy grail of sleep and recovery data. The dissonance between expectation and reality forced a sobering revaluation.

Sirolimus, also known as rapamycin and sold under the brand name Rapamune among others, is a macrolide compound that is used to coat coronary stents, prevent organ transplant rejection, treat a rare lung disease called lymphangioleiomyomatosis, and treat perivascular epithelioid cell tumour (PEComa). This compound also has a use in cardiovascular drug-eluting stent technologies to inhibit restenosis. It is produced by the bacterium Streptomyces hygroscopicus and was isolated for the first time in 1972, from samples of Streptomyces hygroscopicus found on Easter Island. The compound was originally named rapamycin after the native name of the island, Rapa Nui. Sirolimus was initially developed as an antifungal agent. However, this use was abandoned when it was discovered to have potent immunosuppressive and antiproliferative properties due to its ability to inhibit mTOR. It was approved by the US Food and Drug Administration (FDA) in 1999.

Contrary to earlier findings, researchers discovered that the drug actually accelerated biological aging across 16 epigenetic markers. Instead of preserving youth, it might have been fast-forwarding time — at least for Johnson.

So, the next time you are thinking of undergoing some anti-ageing treatment, think twice. Remember the name Bryan Johnson and respect what God wishes to see in you.